SIRT1 is decreased during relapses in patients with multiple sclerosis (Q39036784)

8 September 2017

title

SIRT1 is decreased during relapses in patients with multiple sclerosis (English)

1 reference

8 September 2017

0 references

Cosmin A Tegla

1

1 reference

8 September 2017

Philippe Azimzadeh

2

1 reference

8 September 2017

Maria Andrian-Albescu

3

1 reference

8 September 2017

Alvaro Martin

4

1 reference

8 September 2017

Cornelia D Cudrici

5

1 reference

8 September 2017

Richard Trippe

6

1 reference

8 September 2017

Adam Sugarman

7

1 reference

8 September 2017

Hegang Chen

8

1 reference

8 September 2017

Dallas Boodhoo

9

1 reference

8 September 2017

Sonia I Vlaicu

10

1 reference

8 September 2017

Walter Royal

11

1 reference

8 September 2017

Christopher Bever

12

1 reference

8 September 2017

Violeta Rus

13

1 reference

8 September 2017

Horea Rus

14

1 reference

8 September 2017

publication date

5 January 2014

1 reference

Experimental and Molecular Pathology

8 September 2017

published in

1 reference

8 September 2017

volume

96

1 reference

8 September 2017

issue

2

1 reference

8 September 2017

page(s)

139-148

1 reference

RGC-32 increases p34CDC2 kinase activity and entry of aortic smooth muscle cells into S-phase

8 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXMP.2013.12.010

Molecular cloning and characterization of RGC-32, a novel gene induced by complement activation in oligodendrocytes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXMP.2013.12.010

Biochemical effects of SIRT1 activators

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXMP.2013.12.010

SIRT1 deacetylation and repression of p300 involves lysine residues 1020/1024 within the cell cycle regulatory domain 1

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXMP.2013.12.010

Stress-dependent regulation of FOXO transcription factors by the SIRT1 deacetylase

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXMP.2013.12.010

Transcriptional therapy with the histone deacetylase inhibitor trichostatin A ameliorates experimental autoimmune encephalomyelitis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXMP.2013.12.010

Tissue-specific regulation of SIRT1 by calorie restriction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXMP.2013.12.010

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXMP.2013.12.010

Multiple sclerosis and regulatory T cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXMP.2013.12.010

Dendritic cells are abundant in non-lesional gray matter in multiple sclerosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXMP.2013.12.010

Resveratrol neuroprotection in a chronic mouse model of multiple sclerosis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXMP.2013.12.010

Overexpression of RGC-32 in colon cancer and other tumors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXMP.2013.12.010

Multiple sclerosis--the plaque and its pathogenesis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXMP.2013.12.010

Franklin H. Epstein Lecture: Sirtuins, aging, and medicine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXMP.2013.12.010

Mitochondrial sirtuins: regulators of protein acylation and metabolism

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXMP.2013.12.010

Transcriptional silencing and longevity protein Sir2 is an NAD-dependent histone deacetylase

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXMP.2013.12.010

Decreased severity of experimental autoimmune encephalomyelitis during resveratrol administration is associated with increased IL-17+IL-10+ T cells, CD4(-) IFN-gamma+ cells, and decreased macrophage IL-6 expression

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXMP.2013.12.010

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXMP.2013.12.010

Epigenetic changes in patients with multiple sclerosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXMP.2013.12.010

Epigenetics and miRNAs in the diagnosis and treatment of multiple sclerosis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXMP.2013.12.010

Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXMP.2013.12.010

The development of clinical activity in relapsing-remitting MS is associated with a decrease of FasL mRNA and an increase of Fas mRNA in peripheral blood

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXMP.2013.12.010

Deacetylation of p53 modulates its effect on cell growth and apoptosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXMP.2013.12.010

Dynamic cross-regulation of antigen-specific effector and regulatory T cell subpopulations and microglia in brain autoimmunity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXMP.2013.12.010

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXMP.2013.12.010

Mammalian SIRT1 represses forkhead transcription factors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXMP.2013.12.010

Overexpression of SIRT1 protein in neurons protects against experimental autoimmune encephalomyelitis through activation of multiple SIRT1 targets

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXMP.2013.12.010

The importance of NAD in multiple sclerosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXMP.2013.12.010

Regulatory role of resveratrol on Th17 in autoimmune disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXMP.2013.12.010

Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria”

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXMP.2013.12.010

Interleukin-6 and interleukin-8 protein and gene expression in human arterial atherosclerotic wall

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXMP.2013.12.010

Phosphorylation regulates SIRT1 function.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXMP.2013.12.010

Regulation of histone deacetylase activities

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXMP.2013.12.010

Oral resveratrol reduces neuronal damage in a model of multiple sclerosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXMP.2013.12.010

Resveratrol (trans-3,5,4'-trihydroxystilbene) ameliorates experimental allergic encephalomyelitis, primarily via induction of apoptosis in T cells involving activation of aryl hydrocarbon receptor and estrogen receptor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXMP.2013.12.010

A phylogenetically conserved NAD+-dependent protein deacetylase activity in the Sir2 protein family.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXMP.2013.12.010

Dual role of Response gene to complement-32 in multiple sclerosis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXMP.2013.12.010

Histone acetylation as an epigenetic determinant of long-term transcriptional competence

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXMP.2013.12.010

SIRT1 regulates the histone methyl-transferase SUV39H1 during heterochromatin formation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXMP.2013.12.010

Human SirT1 interacts with histone H1 and promotes formation of facultative heterochromatin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXMP.2013.12.010

Role of C5b-9 complement complex and response gene to complement-32 (RGC-32) in cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXMP.2013.12.010

Epigenetic modifications induced by RGC-32 in colon cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXMP.2013.12.010

Nicotinamide phosphoribosyltransferase protects against ischemic stroke through SIRT1-dependent adenosine monophosphate-activated kinase pathway

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXMP.2013.12.010

Modulation of NF-kappaB-dependent transcription and cell survival by the SIRT1 deacetylase

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXMP.2013.12.010

Role of HDAC3 on p53 expression and apoptosis in T cells of patients with multiple sclerosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXMP.2013.12.010

The type III histone deacetylase Sirt1 is essential for maintenance of T cell tolerance in mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXMP.2013.12.010

SIRT1-dependent regulation of chromatin and transcription: linking NAD(+) metabolism and signaling to the control of cellular functions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXMP.2013.12.010

Histone deacetylase 3 (HDAC3) activity is regulated by interaction with protein serine/threonine phosphatase 4.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXMP.2013.12.010

10.1016/J.YEXMP.2013.12.010

7 January 2021

Identifiers

DOI

1 reference

8 September 2017

1 reference